Researchers at the University of Tsukuba have investigated the changes in the primary evaluation items in phase II clinical ...
The FDA has approved Tremfya as the “first and only” interleukin-23 inhibitor that offers both IV and fully subcutaneous ...
The FDA approved oral iptacopan (Fabhalta; Novartis) to reduce proteinuria in adults with C3 glomerulopathy (C3G), according ...
Discover Skye Bioscience's progress on nimacimab with early trial enrollment, extended treatment protocols, and robust regulatory plans.
Novartis receives third FDA approval for oral Fabhalta® (iptacopan) – the first and only treatment approved in C3 glomerulopathy (C3G) Fabhalta is the only oral alternative complement pathway ...
A treat-to-target study of upadacitinib in atopic dermatitis showed that dosing can be adjusted depending on early patient ...
Novartis also shared results from the open-label phase 3b STRENGTH study of OAV101 IT in SMA patients aged two to less than 18 years who had discontinued treatment with nusinersen or risdiplam, which ...
Sanofi (NASDAQ:SNY) has agreed to acquire an immunology drug from clinical-stage biopharmaceutical company Dren Bio for up to ...
SAVANNAH Phase II trial demonstrated high and durable response rates with savolitinib plus TAGRISSO® in MET-high lung cancer, representing a ...
Novartis' OAV101 IT gene therapy showed positive results in Phase 3 trials for SMA, with data supporting its potential as a ...
A pair of clinical data sets gives Novartis confidence in a new formulation of the company’s gene therapy Zolgensma for the ...
The phase 3 REDEFINE 2 trial has been evaluating once-weekly subcutaneous CagriSema, a fixed dose combination of cagrilintide ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback